These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 8710591)

  • 21. [Oncofetal proteins - their character and clinical significance as tumour-markers (author's transl)].
    Ziegenbein R
    Zentralbl Chir; 1980; 105(23):1537-45. PubMed ID: 6163265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for the clinical use of tumour markers.
    Duffy MJ
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma.
    Lopez JB; Balasegaram M; Timor J; Thambyrajah V
    Malays J Pathol; 1997 Jun; 19(1):53-8. PubMed ID: 10879242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical significance of detecting circulating cancer cells in patients with solid malignancies].
    Majima T; Ichikura T; Mochizuki H
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):769-75. PubMed ID: 11432343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simple mathematical model applied to describing tumour marker data.
    Carl J; Trykker H; Schött P
    Cancer Detect Prev; 1989; 13(5-6):293-9. PubMed ID: 2472886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2002; 56(5):617-34. PubMed ID: 12596691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
    Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tumor markers in malignant tumors].
    Ogreid P
    Tidsskr Nor Laegeforen; 1980 Apr; 100(12):678-9. PubMed ID: 6158119
    [No Abstract]   [Full Text] [Related]  

  • 29. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
    Duffy MJ; van Dalen A; Haglund C; Hansson L; Holinski-Feder E; Klapdor R; Lamerz R; Peltomaki P; Sturgeon C; Topolcan O
    Eur J Cancer; 2007 Jun; 43(9):1348-60. PubMed ID: 17512720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration.
    Chang IH; Ahn SH; Han JH; Kim TH; Kim YS; Myung SC
    J Urol; 2009 Feb; 181(2):567-72; discussion 572-3. PubMed ID: 19084848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer markers of the 1990s. Comparison of the new generation of markers defined by monoclonal antibodies and oncogene probes to prototypic markers.
    Sell S
    Clin Lab Med; 1990 Mar; 10(1):1-37. PubMed ID: 1691962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use.
    Toner GC
    J Clin Oncol; 2004 Oct; 22(19):3842-5. PubMed ID: 15302908
    [No Abstract]   [Full Text] [Related]  

  • 35. [Tumor markers in primary and metastatic liver cancer and cancer of the pancreas].
    Moroz GS; Andreĭchin MA; Kudin AT; Kiĭko LG
    Sov Med; 1988; (12):116-7. PubMed ID: 2468187
    [No Abstract]   [Full Text] [Related]  

  • 36. [Increased carcinoembryonic antigen level: which diagnosis?].
    Gärtner H; Maier KP
    Dtsch Med Wochenschr; 2005 Feb; 130(7):353. PubMed ID: 15756728
    [No Abstract]   [Full Text] [Related]  

  • 37. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
    Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced detection systems for enzyme-linked heterogeneous immunoassays: luminescence.
    Edwards JC; Moon CR
    Immunol Ser; 1990; 53():95-106. PubMed ID: 1713073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of human chorionic gonadotropin compared to CEA in discriminating benign from malignant effusions.
    Lamerz R; Stoetzer OJ; Mezger J; Brandt A; Darsow M; Wilmanns W
    Anticancer Res; 1999; 19(4A):2421-5. PubMed ID: 10470169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.